Claims:

1. The use of a glycosylated polypeptide having an amino terminal chorionic gonadotropin carboxy terminal peptide (CTP), a human growth hormone polypeptide, and two carboxy terminal chorionic gonadotropin CTPs arranged in tandem (CTP-modified hGH), said CTP-modified hGH comprising the amino acid sequence set forth in amino acids 27-301 of SEQ ID NO: 11,
   for the manufacture of a medicament for therapeutic use in treating a growth hormone deficiency in a human child subject, measured by maintaining insulin like growth factor IGF-1 levels within a normal therapeutic range, wherein said therapeutic use comprises a therapeutically effective amount comprising a dose of 10 to 90 milligrams (mg)/week for once a week administration.

2. The use of claim 1, wherein said CTP-modified hGH further comprises an amino terminal signal peptide and said CTP-modified hGH comprises the amino acid sequence set forth in SEQ ID NO:11.

3. The use of claims 1 or 2, wherein said medicament comprising said CTP-modified hGH is an aqueous solution.

4. The use of any one of claims 1 to 3, wherein said aqueous solution is formulated for injection.

5. The use of any one of claims 1-4, wherein said glycosylated polypeptide is encoded by nucleotides 11-913 of SEQ ID NO: 16 or by nucleotides 89-913 of SEQ ID NO: 16.

6. The use of any one of claims 1 to 5, wherein said therapeutically effective amount comprises a once weekly dose of 1 to 60 mg/week.

7. The use of any one of claims 1 to 5, wherein said therapeutically effective amount comprises a once weekly dose of 10 to 20 mg/week.

8. The use of any one of claims 1 to 5, wherein said therapeutically effective amount comprises a once weekly dose of 15 to 25 mg/week.

9. The use of any one of claims 1 to 5, wherein said therapeutically effective amount comprises a once weekly dose of 20 to 40 mg/week.

10. The use of any one of claims 1 to 5, wherein said therapeutically effective amount comprises a once weekly dose of 40 to 60 mg/week.

11. The use of any one of claims 1 to 10, wherein the human child subject is male.

12. The use of any one of claims 1 to 10, wherein said glycosylated polypeptide is for subcutaneous administration to said human child subject.

13. A use of a glycosylated polypeptide having an amino terminal chorionic gonadotropin carboxy terminal peptide (CTP), a human growth hormone polypeptide, and two carboxy terminal chorionic gonadotropin CTPs arranged in tandem(CTP-modified hGH), said CTP-modified hGH comprising the amino acid sequence set forth in amino acids 27-301 of SEQ ID NO: 11 for the manufacture of a medicament for use in the manufacture of a medicament for in treating a growth hormone deficiency in a human child subject or a human adolescent subject, measured by maintaining insulin like growth factor IGF-1 levels within a normal therapeutic range, wherein said therapeutic use comprises a therapeutically effective amount comprising a dose of 10 to 60 milligrams (mg)/week for once a week administration.